Applied DNA Sciences (APDN) Presents At 33rd Annual Roth Virtual Conference - Slideshow

LinearDNA Platform Highlights - Applied DNA Sciences' LinearDNA is positioned as a disruptive nucleic acid manufacturing platform, offering a pure, fast, and flexible alternative to plasmid-based DNA production[4, 7, 17] - The LinearDNA manufacturing process enables large, gram-scale DNA production through PCR, eliminating the need for recombination or plasmids[17] - LinearDNA offers advantages over plasmid DNA, including no risk of antibiotic resistance transfer or endotoxin contamination, and faster manufacturing times (hours vs days to weeks)[20] COVID-19 Related Programs - Applied DNA Sciences has COVID-19 programs focused on detection and protection against coronavirus, including Dx, Surveillance, Variant Detection, and Vaccine Design & Production[5] - The company offers COVID-19 pooled surveillance testing services, utilizing self-collected saliva or anterior nasal swabs, with samples pooled in groups of 5[9, 11] - The Linea™ COVID-19 Assay Kit discriminates virus-positive samples for the 69-70del mutation, enabling efficient and cost-effective variant spread monitoring[16] Vaccine Development - Applied DNA Sciences is developing LinearDNA COVID-19 vaccine candidates for both humans and veterinary use, in partnership with Takis Biotech[9, 26] - Preclinical studies of LinearDNA COVID-19 human vaccine candidates yielded strong antibody and T cell responses in mice, with seroconversion in all mice to produce IgG against SARS-CoV-2 Spike protein by Day 14[26] - The company is pursuing a USDA APHIS conditional license for its veterinary vaccine to prevent SARS-CoV-2 in animals, with Phase I and II trials planned[27] Commercialization and Pipeline - Applied DNA Sciences is pursuing a multi-faceted commercialization strategy for Linear DNA, including CRO, CMO, strategic alliances, and proprietary therapeutics[23] - The company has multiple revenue-generating development customers and is developing a cancer vaccine candidate in partnership with Takis/Evvivax SRL[25] - The development pipeline includes preclinical and clinical programs in veterinary anti-cancer vaccines, LinearDNA COVID-19 human and veterinary vaccine candidates, and anti-CD19b CAR T adoptive cell therapy[26]